secwatch.observer — SEC 8-K summary
======================================

Issuer:     Citius Pharmaceuticals, Inc. (CTXR)
CIK:        0001506251
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001213900-24-066357
Event type: regulatory
Sentiment:  positive
Materiality: 0.95
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Citius Pharma receives FDA approval for LYMPHIR (denileukin diftitox-cxdl) in r/r CTCL
--------------------------------------------------------------------------------

- Phase 3 study showed 36.2% ORR, 8.7% complete response, median time to response 1.41 months.
- First FDA-approved product for Citius; launch expected within next five months.
- Boxed warning for capillary leak syndrome; postmarketing requirement to assess visual impairment risk.
- Only systemic therapy targeting IL-2 receptor on malignant T-cells and Tregs for CTCL.
- US market for r/r CTCL estimated at $300–$400 million; no cumulative toxicity observed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506251/000121390024066357/0001213900-24-066357-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506251/000121390024066357/ea0210874-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-066357

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer